This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Eikonizo Therapeutics, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Stéphane Ouellet: Innovator in HDAC6 Inhibition
Introduction
Stéphane Ouellet is a notable inventor based in Sudbury, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit HDAC6, a protein linked to various diseases.
Latest Patents
Stéphane Ouellet holds a patent for "HDAC6 inhibitors and uses thereof." This patent includes compounds that inhibit HDAC6, which is associated with diseases such as cancer and neurological disorders. The patent also covers pharmaceutical compositions and kits that utilize these compounds, along with methods for treating HDAC6-related diseases, including Alzheimer's disease and cancer.
Career Highlights
Ouellet's work has been instrumental in advancing therapeutic options for patients suffering from HDAC6-related conditions. His innovative approach to drug development has positioned him as a key figure in the pharmaceutical industry.
Collaborations
Stéphane Ouellet collaborates with Jacob Matthew Hooker, enhancing the research and development efforts at Eikonizo Therapeutics, Inc. Their partnership focuses on creating effective treatments for complex diseases.
Conclusion
Stéphane Ouellet's contributions to the field of HDAC6 inhibition demonstrate his commitment to improving healthcare through innovation. His work continues to pave the way for new therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile